FoxWayne Enterprises Acquisition (FoxWayne Enterprises Acquisition) 3-Year EBITDA Growth Rate : 0.00% (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is FoxWayne Enterprises Acquisition 3-Year EBITDA Growth Rate?

FoxWayne Enterprises Acquisition's EBITDA per Share for the three months ended in Sep. 2022 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Competitive Comparison of FoxWayne Enterprises Acquisition's 3-Year EBITDA Growth Rate

For the Shell Companies subindustry, FoxWayne Enterprises Acquisition's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FoxWayne Enterprises Acquisition's 3-Year EBITDA Growth Rate Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, FoxWayne Enterprises Acquisition's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where FoxWayne Enterprises Acquisition's 3-Year EBITDA Growth Rate falls into.

FoxWayne Enterprises Acquisition 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

FoxWayne Enterprises Acquisition (NAS:FOXWU) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

FoxWayne Enterprises Acquisition 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of FoxWayne Enterprises Acquisition's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

FoxWayne Enterprises Acquisition (FoxWayne Enterprises Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » FoxWayne Enterprises Acquisition Corp (NAS:FOXWU) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020

Website

https://www.foxwayne.com

FoxWayne Enterprises Acquisition Corp is a blank check company.

Executives

Robb Knie	director, officer: Chairman and CEO	C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Jonathan Hale Zippin	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Foxwayne Enterprises Acquisition Sponsor Llc	director, 10 percent owner, officer: Chairman and CEO	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Michael Reavey	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Sundeep Agrawal	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020

FoxWayne Enterprises Acquisition (FoxWayne Enterprises Acquisition) Headlines

From GuruFocus

Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company

By PRNewswire PRNewswire • 12-07-2021

FoxWayne Enterprises Acquisition Corp. Announces Securities to Commence Separate Trading

By PRNewswire PRNewswire • 02-26-2021

Investor Alert: The M&A Class Action Firm Announces an Investigation of the Merger of FoxWayne Enterprises Acquisition Corp. - FOXW

By PRNewswire PRNewswire • 12-16-2021

FoxWayne Enterprises Acquisition Corp. Announces Pricing of $50,000,000 Initial Public Offering

By PRNewswire PRNewswire • 01-20-2021

Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

By PRNewswire PRNewswire • 03-04-2022

Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge with Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company

By GuruFocusNews GuruFocusNews • 12-07-2021

FOXWAYNE ENTERPRISES ACQUISITION CORP. ANNOUNCES CHANGE OF SPECIAL MEETING DATE AND INCREASE IN ITS CONTRIBUTION TO THE TRUST ACCOUNT FOR EXTENSION PROPOSAL

By PRNewswire PRNewswire • 11-29-2022

FoxWayne Enterprises Acquisition Corp. Announces Closing of $57,500,000 Initial Public Offering Including Full Exercise of the Underwriters' Over-Allotment Option

By PRNewswire PRNewswire • 01-22-2021